Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective.
作者： Choongho Lee , Won Jun Choi
DOI: 10.1007/S12272-020-01301-7
关键词:
摘要: The novel beta coronavirus (SARS-CoV-2, designated as COVID-19) that is responsible for severe acute respiratory syndrome has devastated the global economy and health care system. Since COVID-19 changed the definition of “normal” in ordinary life around the world, the development of effective therapeutics and preventive measures is desperately needed to fight SARS-CoV-2 infection and restore normalcy. A clear understanding of COVID-19 pathogenesis is crucial in providing the scientific rationale necessary to develop anti …
springer.com
sci-hub.st 参考文章(136)
Paolo Verdecchia, Claudio Cavallini, Antonio Spanevello, Fabio Angeli, The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. European Journal of Internal Medicine. ,vol. 76, pp. 14- 20 ,(2020) , 10.1016/J.EJIM.2020.04.037
Brandon Michael Henry, Jens Vikse, Stefanie Benoit, Emmanuel J. Favaloro, Giuseppe Lippi, Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clinica Chimica Acta. ,vol. 507, pp. 167- 173 ,(2020) , 10.1016/J.CCA.2020.04.027
Claire S. Whyte, Gael B. Morrow, Joanne L. Mitchell, Pratima Chowdary, Nicola J. Mutch, Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. Journal of Thrombosis and Haemostasis. ,vol. 18, pp. 1548- 1555 ,(2020) , 10.1111/JTH.14872
Francesca Coperchini, Luca Chiovato, Laura Croce, Flavia Magri, Mario Rotondi, The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine & Growth Factor Reviews. ,vol. 53, pp. 25- 32 ,(2020) , 10.1016/J.CYTOGFR.2020.05.003
Andrea Picchianti Diamanti, Maria Manuela Rosado, Claudio Pioli, Giorgio Sesti, Bruno Laganà, Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity. International Journal of Molecular Sciences. ,vol. 21, pp. 3330- 3330 ,(2020) , 10.3390/IJMS21093330
Jaume Alijotas-Reig, Enrique Esteve-Valverde, Cristina Belizna, Albert Selva-O'Callaghan, Josep Pardos-Gea, Angela Quintana, Arsene Mekinian, Ariadna Anunciacion-Llunell, Francesc Miró-Mur, Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmunity Reviews. ,vol. 19, pp. 102569- ,(2020) , 10.1016/J.AUTREV.2020.102569
Christian Foerch, Lucie Friedauer, Boris Bauer, Timo Wolf, Elisabeth H. Adam, Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Multiple sclerosis and related disorders. ,vol. 42, pp. 102180- 102180 ,(2020) , 10.1016/J.MSARD.2020.102180
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, Anoop Misra, Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. ,vol. 14, pp. 641- 648 ,(2020) , 10.1016/J.DSX.2020.05.018
Amene Saghazadeh, Nima Rezaei, Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids. International Immunopharmacology. ,vol. 84, pp. 106560- ,(2020) , 10.1016/J.INTIMP.2020.106560
Mahdi Barzegar, Omid Mirmosayyeb, Nasim Nehzat, Reza Sarrafi, Farzin Khorvash, Amir-Hadi Maghzi, Vahid Shaygannejad, COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neuroimmunology and Neuroinflammation. ,vol. 7, ,(2020) , 10.1212/NXI.0000000000000753